Peptide Therapeutics Market Size is Expected to Reach USD 85.9 billion, Advancing at a CAGR of 9.6% by 2031: Transparency Market Research Inc.
September 04, 2024 09:43 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The global peptide therapeutics market (ペプチド治療薬市場) is estimated to thrive at a CAGR of...
Bioxodes annonce la recommandation positive du DMC pour son essai de phase 2a dans le traitement des AVC hémorragiques avec BIOX-101
August 21, 2024 02:30 ET
|
Bioxodes
Le Comité de surveillance des données (DMC, Data Monitoring Committee) a recommandé la poursuite de l’étude après l’examen planifié des données provenant des 8 premiers patients L’analyse des...
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
August 21, 2024 02:30 ET
|
Bioxodes
Planned Data Monitoring Committee (DMC) meeting recommended continuation of the study after reviewing data from the first 8 patients Interim data from 16 patients scheduled around the end of 2024 ...
[Latest] Global Epigenetics Diagnostic Market Size/Share Worth USD 41.6 Billion by 2033 at a 14.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
July 23, 2024 03:30 ET
|
Custom Market Insights
Austin, TX, USA, July 23, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Epigenetics Diagnostic Market Size, Trends and Insights By Product Type...
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
July 08, 2024 07:30 ET
|
Amarin Corporation plc
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG)...
Bioxodes franchit une première étape dans le recrutement de patients pour son essai de phase 2a dans le traitement des hémorragies intracérébrales avec BIOX-101
June 27, 2024 02:30 ET
|
Bioxodes
Candidat médicament « first-in-class » évalué chez les huit premiers patients Gosselies (Belgique), le 27 juin 2024 – Bioxodes SA, société biopharmaceutique en phase clinique développant de...
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke
June 27, 2024 02:30 ET
|
Bioxodes
First-in-class drug candidate evaluated in first eight patients Gosselies (Belgium), June 27, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for...
[Latest] Global Gym Equipment Market Size/Share Worth USD 27,420.9 Million by 2033 at a 4.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
June 19, 2024 04:30 ET
|
Custom Market Insights
Austin, TX, USA, June 19, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Gym Equipment Market Size, Trends and Insights By Product Type (Cardiovascular...
New Findings Revealed on Kyolic Aged Garlic Extract Research at 7th Annual International Garlic Symposium
June 05, 2024 10:00 ET
|
Wakunaga of America
MUNICH, June 05, 2024 (GLOBE NEWSWIRE) -- The latest research on Wakunaga of America’s Aged Garlic Extract (AGE) was presented at the 7th International Garlic Symposium: Frontiers of Garlic Research...
L'Office européen des brevets notifie Bioxodes de son intention de délivrer un brevet offrant une large protection à son actif principal dans le traitement des thrombo-inflammations
May 16, 2024 03:04 ET
|
Bioxodes
Gosselies (Belgique), le 16 mai 2024 – Bioxodes SA, société biopharmaceutique de stade clinique développant de nouvelles thérapies dédiées à la prévention et au traitement de maladies thrombotiques et...